Opinion|Videos|January 22, 2025
Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia
Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on data updates presented for the AUGMENT-101 trial.
- Given the 64% ORR and 23% CR/CRh rate observed with revumenib in patients with heavily preated pretreated KMT2A-rearranged acute leukemia patients, how do you see this therapy reshaping the treatment landscape for this high-risk population?
- Briefly comment on the clinical implications, particularly in the context of bridging to stem cell transplantation.?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
5